H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Amylyx (AMLX) to $20 from $16 and keeps a Buy rating on the shares. With the pivotal LUCIDITY trial on track for topline data in 2026, the firm remains “enthusiastic about avexitide” and thinks it is positioned to become the first potential therapy for PBH, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Reports Strong Q3 2025 Results
- Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges
- Buy Rating for Amylyx Pharmaceuticals: Strong Financial Health and Promising Pipeline Developments
- Buy Rating for Amylyx Pharmaceuticals: Promising Phase III Study and Market Potential for Avexitide
- Amylyx reports Q3 EPS (37c), consensus (43c)